Physician profile
Steven Koerner
NPI 1558434308
$2,221.41
in general payments reported to CMS, 2019-2025
22 companies · $266 in 2025
The $266 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $257 · 2020: $41.42 · 2021: $247 · 2022: $392 · 2023: $538 · 2024: $480 · 2025: $266.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,194 · Education: $89.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,194.02 |
| Education | $89.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $764.04 | 2019-2025 | Stelara, Tremfya, Simponi |
| Abbvie INC. | $563.45 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $120.12 | 2020-2024 | Entyvio |
| Qol Medical, LLC | $112.61 | 2019-2025 | Sucraid, Sucraid |
| Merck Sharp & Dohme LLC | $110.85 | 2019-2024 | Dificid |
| Celgene Corporation | $92.04 | 2021-2024 | Zeposia |
| Gilead Sciences, INC. | $81.91 | 2019-2025 | |
| Ferring Pharmaceuticals INC. | $62.76 | 2022-2023 | Rebyota |
| Phathom Pharmaceuticals, INC. | $62.05 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.74 | 2019-2024 | Xifaxan |
| Pfizer INC. | $30.21 | 2022-2024 | |
| Madrigal Pharmaceuticals | $20.11 | 2025 | Rezdiffra |
| Intercept Pharmaceuticals, INC. | $18.96 | 2025 | |
| Lilly USA, LLC | $18.80 | 2024 | |
| Ardelyx, INC. | $18.48 | 2024 | Ibsrela |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Capsovision, INC. | $17.99 | 2025 | Capsocam Plus |
| Exact Sciences Corporation | $17.33 | 2024 | Cologuard Collection Kit |
| Genzyme Corporation | $17.32 | 2022 | |
| Aimmune Therapeutics, INC. | $16.13 | 2025 | Zenpep |
| Redhill Biopharma INC. | $13.31 | 2021 | |
| Ucb, INC. | $11.61 | 2019 | |
| Thd America, INC. | $5.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Koerner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.